| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A Business Intelligence Solution to Pharmacovigilance Signal Tracking and Management: One Mid-Size Pharma’s Experience
|
Patadia, Vaishali K.
|
|
2015
|
|
4 |
p. 197-201
|
artikel
|
| 2 |
Adverse Drug Reaction Risk Measures: A Comparison of Estimates from Drug Surveillance and Randomised Trials
|
Beau-Lejdstrom, Raphaelle
|
|
2019
|
|
4 |
p. 331-339
|
artikel
|
| 3 |
Agomelatine Drug Utilisation Study in Selected European Countries: A Multinational, Observational Study to Assess Effectiveness of Risk-Minimisation Measures
|
Jacquot, Emmanuelle
|
|
2019
|
|
4 |
p. 311-319
|
artikel
|
| 4 |
An Analysis of US Food and Drug Administration Clinical Hold Orders for Drugs and Biologics: A Prospective Study Between 2008 and 2014
|
Boudes, Pol F.
|
|
2015
|
|
4 |
p. 203-209
|
artikel
|
| 5 |
Approval of Generic Fluticasone Propionate/Salmeterol Xinafoate Dry Powder Inhalers in the US: A Difficult Exercise in Regulatory Science
|
Fuglsang, Anders
|
|
2014
|
|
4 |
p. 169-173
|
artikel
|
| 6 |
Assessing the Value of System Theoretic Process Analysis in a Pharmacovigilance Process: An Example Using Signal Management
|
Adesina, Ajibade A.
|
|
2017
|
|
4 |
p. 267-278
|
artikel
|
| 7 |
Association of Adverse Drug Events with Hospitalization Outcomes and Costs in Older Adults in the USA using the Nationwide Readmissions Database
|
Riaz, Munaza
|
|
2019
|
|
4 |
p. 321-329
|
artikel
|
| 8 |
A Systematic Review to Identify the Use of Preference Elicitation Methods in Healthcare Decision Making
|
Weernink, Marieke G. M.
|
|
2014
|
|
4 |
p. 175-185
|
artikel
|
| 9 |
Bioequivalence
|
Patterson, Scott D.
|
|
|
|
4 |
p. 243-250
|
artikel
|
| 10 |
Biological weapons and the pharmaceutical industry
|
Gorka, S.
|
|
|
|
4 |
p. 213-218
|
artikel
|
| 11 |
Challenges in Conducting Clinical Trials for Pharmacotherapies in Fragile X Syndrome: Lessons Learned
|
Harkins, Christina M.
|
|
2017
|
|
4 |
p. 235-244
|
artikel
|
| 12 |
Continuing Medical Education and Professional Development in the European Union
|
Silva, Honorio
|
|
2012
|
|
4 |
p. 223-233
|
artikel
|
| 13 |
Current Prospects of Molecular Therapeutics in Head and Neck Squamous Cell Carcinoma
|
Devaraja, K.
|
|
2019
|
|
4 |
p. 269-289
|
artikel
|
| 14 |
Current Trends in the Clinical Development of Antibody-Drug Conjugates in Oncology
|
Dott, Joseph
|
|
2018
|
|
4 |
p. 259-273
|
artikel
|
| 15 |
Different Weights of the Evidence-Based Medicine Triad in Regulatory, Health Technology Assessment, and Clinical Decision Making
|
Schlegl, Evelyn
|
|
2017
|
|
4 |
p. 213-216
|
artikel
|
| 16 |
Drugs in Clinical Development for Attention-Deficit/Hyperactivity Disorder: Summary and Table
|
|
|
2013
|
|
4 |
p. 245-248
|
artikel
|
| 17 |
Drugs in Clinical Development for Osteoporosis
|
|
|
2012
|
|
4 |
p. 249-252
|
artikel
|
| 18 |
Drugs in Clinical Development for Parkinson’s Disease: Summary and Table
|
|
|
2015
|
|
4 |
p. 219-225
|
artikel
|
| 19 |
Drugs in Clinical Development for Rheumatoid Arthritis Summary and Table
|
|
|
2014
|
|
4 |
p. 195-213
|
artikel
|
| 20 |
Ethical Issues in Phase I Cancer Clinical Trials
|
Peppercorn, Jeffrey
|
|
|
|
4 |
p. 233-242
|
artikel
|
| 21 |
EU Compassionate Use Programmes (CUPs)
|
Sou, Hélène
|
|
2010
|
|
4 |
p. 223-229
|
artikel
|
| 22 |
European Respiratory Society
|
Kitler, Mary Ellen
|
|
|
|
4 |
p. 243-246
|
artikel
|
| 23 |
Excipients in Neonatal Medicinal Products: Never Prescribed, Commonly Administered
|
Valeur, Kristine Svinning
|
|
2018
|
|
4 |
p. 251-258
|
artikel
|
| 24 |
Forum
|
|
|
2013
|
|
4 |
p. 249-257
|
artikel
|
| 25 |
Forum
|
|
|
2014
|
|
4 |
p. 215-222
|
artikel
|
| 26 |
Forum
|
|
|
2017
|
|
4 |
p. 279-292
|
artikel
|
| 27 |
Forum
|
|
|
2018
|
|
4 |
p. 295-314
|
artikel
|
| 28 |
Forum
|
|
|
2015
|
|
4 |
p. 227-239
|
artikel
|
| 29 |
Forum
|
|
|
2016
|
|
4 |
p. 233-245
|
artikel
|
| 30 |
Forum
|
|
|
2012
|
|
4 |
p. 257-269
|
artikel
|
| 31 |
Forum
|
|
|
2010
|
|
4 |
p. 239-253
|
artikel
|
| 32 |
Forum
|
|
|
2019
|
|
4 |
p. 341-359
|
artikel
|
| 33 |
Forum
|
|
|
|
|
4 |
p. 269-272
|
artikel
|
| 34 |
Harmonised European Standards as a Basis for the Safe Use of Herbal Medicinal Products and Their Marketing Authorisation in European Union Member States
|
Peschel, Wieland
|
|
2018
|
|
4 |
p. 275-293
|
artikel
|
| 35 |
Increasing the Number of Spontaneous ADE Reports in a Danish Region: A Retrospective Analysis
|
Sørup, Freja Karuna Hemmingsen
|
|
2015
|
|
4 |
p. 211-217
|
artikel
|
| 36 |
Integrating Genomics into Drug Discovery and Development: Challenges and Aspirations
|
Raja, Rajiv
|
|
2017
|
|
4 |
p. 217-233
|
artikel
|
| 37 |
Journal Watch
|
|
|
2014
|
|
4 |
p. 223-238
|
artikel
|
| 38 |
Journal Watch
|
|
|
2012
|
|
4 |
p. 271-282
|
artikel
|
| 39 |
Journal Watch
|
|
|
2010
|
|
4 |
p. 255-266
|
artikel
|
| 40 |
Journal Watch
|
|
|
2013
|
|
4 |
p. 259-271
|
artikel
|
| 41 |
Lay Summaries of Clinical Study Results: An Overview
|
Barnes, Amber
|
|
2019
|
|
4 |
p. 261-268
|
artikel
|
| 42 |
Major Pharmaceutical Conferences
|
|
|
2010
|
|
4 |
p. 267-270
|
artikel
|
| 43 |
Major Pharmaceutical Conferences and Courses
|
|
|
2013
|
|
4 |
p. 273-278
|
artikel
|
| 44 |
Major Pharmaceutical Conferences and Courses
|
|
|
2014
|
|
4 |
p. 239-244
|
artikel
|
| 45 |
Major Pharmaceutical Conferences and Courses
|
|
|
2017
|
|
4 |
p. 293-296
|
artikel
|
| 46 |
Major Pharmaceutical Conferences and Courses
|
|
|
2018
|
|
4 |
p. 315-318
|
artikel
|
| 47 |
Major Pharmaceutical Conferences and Courses
|
|
|
2015
|
|
4 |
p. 241-245
|
artikel
|
| 48 |
Major Pharmaceutical Conferences and Courses
|
|
|
2016
|
|
4 |
p. 247-251
|
artikel
|
| 49 |
Major Pharmaceutical Conferences and Courses
|
|
|
2012
|
|
4 |
p. 283-286
|
artikel
|
| 50 |
Major Pharmaceutical Conferences and Courses
|
|
|
2019
|
|
4 |
p. 361-365
|
artikel
|
| 51 |
Measuring and Improving Physician Knowledge of Safety Risks Using Traditional and Online Methods in Pharmacovigilance
|
Liede, Alexander
|
|
2017
|
|
4 |
p. 257-266
|
artikel
|
| 52 |
Myths in Clinical Pharmacology
|
Fox, Anthony W.
|
|
2010
|
|
4 |
p. 209-210
|
artikel
|
| 53 |
Nutraceuticals: Reviewing their Role in Chronic Disease Prevention and Management
|
Bergamin, Amanda
|
|
2019
|
|
4 |
p. 291-309
|
artikel
|
| 54 |
Open Access Pharmacovigilance Databases: Analysis of 11 Databases
|
Fouretier, Alice
|
|
2016
|
|
4 |
p. 221-231
|
artikel
|
| 55 |
Perspectives on the Emergence of Pharmacovigilance in Public Health Programmes in South Africa
|
Dheda, Mukesh
|
|
2016
|
|
4 |
p. 213-219
|
artikel
|
| 56 |
Pharmaceutical Medicine in Mexico
|
Cohen-Muñoz, Vanessa
|
|
2010
|
|
4 |
p. 211-218
|
artikel
|
| 57 |
Pharmaceutical Medicine Teaching Syllabus for Medical Writers
|
Bucurescu, Septimiu
|
|
2010
|
|
4 |
p. 219-222
|
artikel
|
| 58 |
Phase III Trial of Dalcetrapib
|
Sweetlove, Mel
|
|
2012
|
|
4 |
p. 253-256
|
artikel
|
| 59 |
Promotional Review: Principles and Practice
|
Allen, Christopher
|
|
2016
|
|
4 |
p. 187-191
|
artikel
|
| 60 |
Regulating Electronic Cigarettes: Not Tobacco and Not (Yet) Therapy
|
Anthopoulou, Eva
|
|
2016
|
|
4 |
p. 203-211
|
artikel
|
| 61 |
Retraction Note to: The Longitudinal Incidence of Human Papillomavirus Vaccination in Spanish Primary Care in the First 6 Years After Approval
|
Martín-Merino, Elisa
|
|
2019
|
|
4 |
p. 367
|
artikel
|
| 62 |
Risk Perceptions in Diabetic Patients Who Have Experienced Adverse Events: Implications for Patient Involvement in Regulatory Decisions
|
Sachs, Mikkel Lindskov
|
|
2017
|
|
4 |
p. 245-255
|
artikel
|
| 63 |
Rule of Law and State Capacity: Keys to Market Access in Developing and Resource-Constrained Markets
|
Taylor, D. Wayne
|
|
2016
|
|
4 |
p. 193-201
|
artikel
|
| 64 |
Should We Legalise Recreational Drugs? An Ethical Question for Animals and Humans
|
Shaw, Ian C.
|
|
2013
|
|
4 |
p. 231-233
|
artikel
|
| 65 |
Surveying US Observational Data Sources and Characteristics for Drug Safety Needs
|
Ryan, Patrick
|
|
2010
|
|
4 |
p. 231-238
|
artikel
|
| 66 |
The Association of Clinical Research Professionals 2012 Global Conference and Exhibition
|
Pochon, Sue
|
|
2012
|
|
4 |
p. 243-248
|
artikel
|
| 67 |
The development of antiviral therapy and vaccines against respiratory syncytial virus and human parainfluenza virus type 3
|
Josey, Elizabeth A.
|
|
|
|
4 |
p. 175-190
|
artikel
|
| 68 |
The European Innovative Medicines Initiative: Progress to Date
|
Faure, Jean-Emmanuel
|
|
2018
|
|
4 |
p. 243-249
|
artikel
|
| 69 |
The Influence of Cost-Effectiveness Evaluations on Reimbursement in Australia: A Retrospective Study of Decisions made by the Pharmaceutical Benefits Advisory Committee
|
Ngo, Phuong
|
|
2014
|
|
4 |
p. 187-193
|
artikel
|
| 70 |
The 102nd Annual Conference of the American Thoracic Society
|
Ranaweera, Anoma
|
|
|
|
4 |
p. 263-268
|
artikel
|
| 71 |
Trends, Outcomes, and Characteristics of Pediatric Oncology Phase I and II Studies: A Systematic Review
|
Lu, Hannah
|
|
2013
|
|
4 |
p. 235-244
|
artikel
|
| 72 |
Use of a Second Generation Antipsychotic among Patients Diagnosed with Major Depressive Disorder in the United States
|
Sclar, David A.
|
|
2012
|
|
4 |
p. 235-241
|
artikel
|
| 73 |
Value-Based Pricing
|
Miller, David W.
|
|
2012
|
|
4 |
p. 217-222
|
artikel
|
Tijdschrift beschrijving